AstraZeneca PLC vs Gilead Sciences, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- AstraZeneca PLC is the larger company by market value: $242.6 B against $193.5 B for Gilead Sciences, Inc., 1.3 times as much (market caps of Aug 1, 2026 for AstraZeneca PLC and Oct 26, 2026 for Gilead Sciences, Inc.). AstraZeneca PLC's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
- AstraZeneca PLC had more revenue: $58.7 B against $29.4 B for Gilead Sciences, Inc., both in the year to December 2025.
- AstraZeneca PLC earned more: net income of $10.2 B against $8.5 B for Gilead Sciences, Inc.
- Gilead Sciences, Inc. keeps more of each dollar of sales: a net margin of 28.9% against 17.4% for AstraZeneca PLC.
- AstraZeneca PLC employs more people: 89,900 against 17,000 at Gilead Sciences, Inc. Each employee brings in about $653,382 of revenue at AstraZeneca PLC and $1,731,941 at Gilead Sciences, Inc.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | AstraZeneca PLC AZN · #76 in the world | Gilead Sciences, Inc. GILD · #104 in the world |
|---|---|---|
| Profile | ||
| Country | 🇬🇧 UK | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1999 | 1987 |
| Size | ||
| Market cap | $242.6 B | $193.5 B |
| Revenue | $58.7 B | $29.4 B |
| Net income | $10.2 B▲ best | $8.5 B |
| Employees | 89,900 | 17,000 |
| Valuation | ||
| P/E ratio | 23.7× | — |
| Price to sales | 4.1× | 6.3× |
| Price to book | 5.0× | 8.5× |
| Free cash flow yield | 4.8% | 4.9%▲ best |
| Profitability | ||
| Gross margin | 81.9% | — |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | — |
| Return on equity | 22.9% | — |
| Return on invested capital | 17.5% | — |
| Growth | ||
| Revenue growth | 8.6% | — |
| Revenue growth, 3 years a year | 9.8% | — |
| Earnings per share growth | 45.3% | — |
| Financial strength | ||
| Debt to equity | 0.5× | — |
| Interest cover | 8.1× | — |
| Cash | ||
| Free cash flow margin | 20.0% | — |
| Shareholder returns | ||
| Dividend yield | 2.0% | — |
| Shareholder yield | 2.3% | — |
| Strength scores | ||
| Piotroski F-score | 8 of 9 | — |
| Altman Z-score zone | safe | — |
| Data as of | Market cap Aug 2026; ratios FY2025 | Market cap Oct 2026 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, AstraZeneca PLC or Gilead Sciences, Inc.?
AstraZeneca PLC is the larger company by market value: $242.6 B against $193.5 B for Gilead Sciences, Inc., 1.3 times as much (market caps of Aug 1, 2026 for AstraZeneca PLC and Oct 26, 2026 for Gilead Sciences, Inc.). AstraZeneca PLC's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
Which makes more money, AstraZeneca PLC or Gilead Sciences, Inc.?
AstraZeneca PLC had more revenue: $58.7 B against $29.4 B for Gilead Sciences, Inc., both in the year to December 2025. AstraZeneca PLC earned more: net income of $10.2 B against $8.5 B for Gilead Sciences, Inc.
Which is more profitable, AstraZeneca PLC or Gilead Sciences, Inc.?
Gilead Sciences, Inc. keeps more of each dollar of sales: a net margin of 28.9% against 17.4% for AstraZeneca PLC.
Which has more employees, AstraZeneca PLC or Gilead Sciences, Inc.?
AstraZeneca PLC employs more people: 89,900 against 17,000 at Gilead Sciences, Inc. Each employee brings in about $653,382 of revenue at AstraZeneca PLC and $1,731,941 at Gilead Sciences, Inc.
More about AstraZeneca PLC
More about Gilead Sciences, Inc.
- Gilead Sciences, Inc.: company page
- Who owns Gilead Sciences, Inc.?
- Gilead Sciences, Inc. market cap history
- Gilead Sciences, Inc. revenue by year
- How many employees does Gilead Sciences, Inc. have?
- Is Gilead Sciences, Inc. cheap or expensive?
- Gilead Sciences, Inc. against its peers: ranks and percentiles
Sources#
Every figure on this page comes from these, with the date shown next to it.